Mupharma

muPharma is a business based in Victoria, Australia that has developed various novel, ultrasound based, non-invasive devices to deliver drugs and vaccines to the body that would ordinarily require injections or other highly invasive delivery means. Principal sites of application include the eye (anterior and posterior segment) and the inside of the mouth. Ocular opportunities include: 1) Non-invasive delivery of biologics (including nucleic acid based personalised drugs and monoclonal antibody drugs) to the retina (via the uveal tract) particularly for the treatment of (dry and wet) AMD, DME and genetically inherited diseases; 2) Non-invasive delivery of Riboflavin to the cornea; and 3) Non-invasive delivery of any chemically synthesised drug to anterior / posterior segments. Immunology opportunities include the creation of protective, long lasting mucosal immunity and systemic against diseases that enter the body via mucous membranes including COVID-19, Influenza, Norovirus, Chlamydia, HIV, Tuberculosis as well as a host of other communicable pathogens.